-+ 0.00%
-+ 0.00%
-+ 0.00%

Inovio publishes Q2 2026 financial results presentation focusing on INO-3107 BLA review progress

PUBT·08/12/2026 21:40:12
Listen to the news
Inovio publishes Q2 2026 financial results presentation focusing on INO-3107 BLA review progress
  • Inovio highlighted FDA review progress for INO-3107, citing a PDUFA target action date of Oct. 30, 2026.
  • Late-cycle review completed. All scheduled FDA inspections conducted. Label negotiations anticipated in September 2026.
  • FDA feedback on the design of a confirmatory trial is expected, following a July clinical informal meeting.
  • Pipeline update noted a positive Phase 3 readout in China for VGX-3100 in HPV 16/18+ cervical dysplasia from partner ApolloBio.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.